Taysha Gene Therapies (TSHA) Change in Account Payables (2020 - 2026)

Taysha Gene Therapies has reported Change in Account Payables for 7 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Change in Account Payables rose 39.65% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $213000.0 (up 103.56% YoY) and the FY2025 annual result came in at -$153000.0, up 94.76% from the prior year.
• Change in Account Payables advanced to $1.3 million in Q1 2026 per TSHA's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.0 million in Q1 2024 and troughed at -$9.4 million in Q3 2022.
• A 5-year average of -$699000.0 and a median of -$1.2 million in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2024: Change in Account Payables soared 31900.0% in 2022, then plunged 191.55% in 2024.
• Over 5 years, Change in Account Payables stood at -$4.6 million in 2022, then surged by 73.19% to -$1.2 million in 2023, then declined by 22.28% to -$1.5 million in 2024, then tumbled by 41.36% to -$2.1 million in 2025, then jumped by 160.63% to $1.3 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $1.3 million, -$2.1 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.